培马贝特降低甘油三酯以降低心血管风险
PROMINENT试验为多国、双盲、随机对照试验,纳入10,497例2型糖尿病、甘油三酯200-499 mg/dL、HDL≤40 mg/dL且LDL≤100 mg/dL的患者,随机接受培马贝特0.2 mg每日两次或安慰剂。中位随访3.4年,培马贝特4个月时降低甘油三酯26.2%、VLDL胆固醇25.8%、残粒胆固醇25.6%、载脂蛋白C-III 27.6%,但主要终点事件风险与安慰剂无显著差异(HR 1.03, 95%CI 0.91-1.15)。培马贝特与肾脏不良事件和静脉血栓栓塞发生率升高相关,与非酒精性脂肪性肝病发生率降低相关。
要点
- 培马贝特0.2 mg每日两次未降低主要心血管复合终点风险(HR 1.03, 95%CI 0.91-1.15),各预设亚组无显著效应修饰。
- 4个月时培马贝特较安慰剂降低甘油三酯26.2%、VLDL胆固醇25.8%、残粒胆固醇25.6%、载脂蛋白C-III 27.6%,载脂蛋白B升高4.8%。
- 培马贝特组严重不良事件总发生率与安慰剂无显著差异,但肾脏不良事件和静脉血栓栓塞发生率更高,非酒精性脂肪性肝病发生率更低。
适用人群与场景
- 2型糖尿病、轻中度高甘油三酯血症(甘油三酯200-499 mg/dL)、HDL胆固醇≤40 mg/dL且LDL胆固醇≤100 mg/dL的患者。
- 患者正在接受指南指导的降脂治疗,或无法耐受他汀类药物不良反应而不能接受他汀治疗。
- 66.9%的患者有既往心血管疾病史。
诊断标准与关键阈值
- 高甘油三酯血症:甘油三酯水平200至499 mg/dL。
- 低HDL胆固醇:HDL胆固醇水平≤40 mg/dL。
- LDL胆固醇水平≤100 mg/dL。
处置流程与药物剂量
- 培马贝特0.2 mg片剂,每日两次口服;对照为匹配的安慰剂。
- 主要疗效终点为非致死性心肌梗死、缺血性卒中、冠状动脉血运重建或心血管原因死亡的复合终点。
红旗征与不能漏的情况
- 培马贝特组肾脏不良事件发生率更高。
- 培马贝特组静脉血栓栓塞发生率更高。
研究设计与关键结果
- PROMINENT试验为多国、双盲、随机、对照试验,纳入10,497例患者,中位随访3.4年。
- 基线中位空腹甘油三酯271 mg/dL,HDL胆固醇33 mg/dL,LDL胆固醇78 mg/dL。
- 4个月时培马贝特较安慰剂:甘油三酯-26.2%,VLDL胆固醇-25.8%,残粒胆固醇-25.6%,载脂蛋白C-III -27.6%,载脂蛋白B +4.8%。
- 主要终点事件在培马贝特组发生572例,安慰剂组560例(HR 1.03;95%CI 0.91-1.15),任何预设亚组均无显著效应修饰。
- 严重不良事件总发生率两组无显著差异;培马贝特组肾脏不良事件和静脉血栓栓塞发生率更高,非酒精性脂肪性肝病发生率更低。
证据类型、等级与局限
- 证据类型:多国、双盲、随机、对照试验。
对床旁实践的改变
- 在2型糖尿病、轻中度高甘油三酯血症及低HDL/LDL胆固醇患者中,培马贝特未降低心血管事件发生率,尽管降低了甘油三酯、VLDL胆固醇、残粒胆固醇和载脂蛋白C-III水平。
- 使用培马贝特时需注意肾脏不良事件和静脉血栓栓塞风险增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels.
METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglyceride level, 200 to 499 mg per deciliter), and high-density lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to receive pemafibrate (0.2-mg tablets twice daily) or matching placebo. Eligible patients were receiving guideline-directed lipid-lowering therapy or could not receive statin therapy without adverse effects and had low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter or lower. The primary efficacy end point was a composite of nonfatal myocardial infarction, ischemic stroke, coronary revascularization, or death from cardiovascular causes.
RESULTS: Among 10,497 patients (66.9% with previous cardiovascular disease), the median baseline fasting triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg per deciliter, and LDL cholesterol level 78 mg per deciliter. The median follow-up was 3.4 years. As compared with placebo, the effects of pemafibrate on lipid levels at 4 months were -26.2% for triglycerides, -25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for remnant cholesterol (cholesterol transported in triglyceride-rich lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point event occurred in 572 patients in the pemafibrate group and in 560 of those in the placebo group (hazard ratio, 1.03; 95% confidence interval, 0.91 to 1.15), with no apparent effect modification in any prespecified subgroup. The overall incidence of serious adverse events did not differ significantly between the groups, but pemafibrate was associated with a higher incidence of adverse renal events and venous thromboembolism and a lower incidence of nonalcoholic fatty liver disease.
CONCLUSIONS: Among patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and low HDL and LDL cholesterol levels, the incidence of cardiovascular events was not lower among those who received pemafibrate than among those who received placebo, although pemafibrate lowered triglyceride, VLDL cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number, NCT03071692.).
参考来源
- Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022. PMID: 36342113. doi:10.1056/NEJMoa2210645
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。